Trillium Therapeutics Inc.
(“Trillium” or the “Company”) (NASDAQ/TSX:
TRIL), a clinical stage immuno-oncology company developing
innovative therapies for the treatment of cancer, today announced
the formation of a Scientific Advisory Board (“SAB”), including
Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD,
Steven Rosen, MD, and Jeff Settleman, PhD.
“It is a true privilege to announce this SAB,
comprised of leading experts who have had major formative impact on
the field of oncology/immuno-oncology over the past 25 years,” said
Jan Skvarka, Trillium President and Chief Executive Officer. “Their
combined resume includes several of the most groundbreaking
oncology drugs or underlying scientific discoveries, including the
PD-1/PD-L1 class, Adcetris, interferon, Iressa, Lemtrada, Velcade,
Tarceva, Taxol, and Xalkori, among others. We are looking forward
to their guidance as we continue expanding our research and
development activities.”
Members of the Trillium’s SAB include:
Karen J. Ferrante, MD – Dr.
Ferrante is a hematologist-oncologist with 25 years of experience
in oncology drug development. She was the Head of R&D and CMO
at Tokai Pharmaceuticals, and Head of the Oncology Therapeutic Area
at Takeda and CMO at Millennium Pharmaceuticals, after holding a
variety of roles in oncology clinical development at Pfizer and
BMS. During her career she was involved in the clinical development
of a number of important cancer therapeutics including Taxol,
Tarceva and Velcade.
Gordon Freeman, PhD – Dr.
Freeman is an immunology researcher in the Department of Medical
Oncology at Dana-Farber Cancer Institute and a Professor of
Medicine at Harvard Medical School. Dr. Freeman is best known for
the discovery of the PD-1/PD-L1 pathway, which provided the
foundation for developing immune checkpoint blockade
immunotherapies. Dr. Freeman is the 2014 recipient of the William
B. Coley Award for Distinguished Research in Tumor Immunology, the
2017 recipient of the Warren Alpert Foundation award, and a 2020
co-recipient of the Richard V. Smalley, MD award, the highest award
of the Society for Immunotherapy of Cancer.
Tom Reynolds, MD,
PhD – Dr. Reynolds served as Chief Medical Officer of
Seattle Genetics, where he was responsible for building and leading
an integrated clinical development, regulatory and medical affairs
organization, highlighted by the development and approval of
Adcetris. Previously, Dr. Reynolds served at ZymoGenetics (acquired
by Bristol-Myers Squibb in 2010), most recently as VP Medical
Affairs, where he oversaw the clinical development and regulatory
filing of recothrom, and VP Clinical Affairs at Targeted
Genetics.
Steven T. Rosen, MD – Dr. Rosen
is the Provost and Chief Scientific Officer of the City of Hope
National Medical Center in Duarte, California. In addition to
directing City of Hope’s Comprehensive Cancer Center, Dr. Rosen
leads the Beckman Research Institute at City of Hope. Previously,
Dr. Rosen was the director of the Robert H. Lurie Comprehensive
Cancer Center at Northwestern University. In 2015, Dr. Rosen
received a lifetime achievement award from the Israel Cancer
Research Fund for his work in cancer research. His main areas of
research involve the development of new treatments, particularly
for hematologic malignancies.
Jeff
Settleman, PhD – Dr. Settleman is
the Chief Scientific Officer for Oncology R&D at Pfizer, where
he leads all oncology research from discovery to proof of concept
clinical studies. Prior to Pfizer, Dr. Settleman was the Head of
Oncology Research at Calico Life Sciences, and the Head of
Discovery Oncology at Genentech, following an 18 year career in
academia as a Professor at the Harvard School of Medicine, a
Director of the Center for Molecular Therapeutics and Scientific
Director of the Massachusetts General Hospital Cancer Center, as
well as the Head of the Cancer Cell Biology program of the
Dana-Farber/Harvard Cancer Center.
About Trillium
Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). Forward-looking statements in this press release
include statements about, without limitation, the membership and
our plans for our scientific advisory board. With respect to the
forward-looking statements contained in this press release,
Trillium has made numerous assumptions regarding, among other
things: the impact of the COVID-19 pandemic on its operations, the
effectiveness and timeliness of preclinical and clinical trials;
and the completeness, accuracy and usefulness of the data. While
Trillium considers these assumptions to be reasonable, these
assumptions are inherently subject to significant scientific,
business, economic, competitive, market and social uncertainties
and contingencies. Additionally, there are known and unknown risk
factors that could cause Trillium's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained in this press release. A
discussion of risks and uncertainties facing Trillium appears in
Trillium's Annual Information Form for the year ended December 31,
2019 filed with Canadian securities authorities and on Form 40-F
with the U.S. Securities Exchange Commission, each as updated by
Trillium's continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Trillium disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Investor Relations:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown
Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024